Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study

BACKGROUND/OBJECTIVE: This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late disease (LD). METHODS: The phase 3, double-blind, GO-ALIVE study randomized patients to IV golimumab 2 mg/kg at weeks 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul A., Shiff, Natalie J., Gong, Cinty, Hsia, Elizabeth C., Lo, Kim Hung, Kim, Lilliane, Xu, Stephen, Reveille, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336574/
https://www.ncbi.nlm.nih.gov/pubmed/35653615
http://dx.doi.org/10.1097/RHU.0000000000001853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336574/
https://www.ncbi.nlm.nih.gov/pubmed/35653615
http://dx.doi.org/10.1097/RHU.0000000000001853

Ejemplares similares